← All trials
NCT05620134
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2022
- Primary completion
- Oct 17, 2025
- Completion date
- Feb 20, 2026
- First posted
- Nov 17, 2022
- Last posted
- Nov 17, 2022
- Enrollment
- 149
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Salubris Biotherapeutics IncLead sponsor
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Ovarian Epithelial
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Melanoma
- Neoplasms
- Pancreatic Neoplasms
- Skin Neoplasms
- Stomach Neoplasms
- Thyroid Neoplasms
- Colorectal Neoplasms
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.